Cleared Special

K092170 - STA LIATEST FREE PS

K092170 is the FDA 510(k) clearance for STA LIATEST FREE PS by Diagnostica Stago, Inc.. It is a Class 2 Hematology device (product code GGP) cleared through the Special 510(k) pathway after a 154-day FDA review.

K092170 · Diagnostica Stago, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2009
Decision
154d
Days
Class 2
Risk

K092170 is an FDA 510(k) clearance for the STA LIATEST FREE PS. Classified as Test, Qualitative And Quantitative Factor Deficiency (product code GGP), Class II - Special Controls.

Submitted by Diagnostica Stago, Inc. (Parisppany, US). The FDA issued a Cleared decision on December 22, 2009 after a review of 154 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Standard predicate reliance. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Diagnostica Stago, Inc. devices

Submission Details

510(k) Number K092170 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 21, 2009
Decision Date December 22, 2009
Days to Decision 154 days
Submission Type Special
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
41d slower than avg
Panel avg: 113d · This submission: 154d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code GGP Test, Qualitative And Quantitative Factor Deficiency
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GGP Test, Qualitative And Quantitative Factor Deficiency

All 127
Devices cleared under the same product code (GGP) and FDA review panel - the closest regulatory comparables to K092170.
INNOVANCE Free PS Ag
K181525 · Siemens Healthcare Diagnostics Products GmbH · Sep 2018
HEMOSIL VON WILLEBRAND ACTIVITY ASSAY
K133005 · Instrumentation Laboratory CO · Mar 2014
HEMOSIL PROTEIN S ACTIVITY ASSAY
K102164 · Instrumentation Laboratory CO · Mar 2011
HEMOSIL PROCLOT
K070635 · Instrumentation Laboratory CO · Mar 2007
TRIAGE PROTEIN C TEST
K062530 · Biosite Incorporated · Jan 2007
HEMOSIL PROTEIN C
K062430 · Instrumentation Laboratory CO · Sep 2006